Cancer drug developer obtains $32.5M in private placement

05/3/2013 | American City Business Journals

Celator Pharmaceuticals, a New Jersey-based firm specializing in cancer drugs, secured $32.5 million in a private placement led by Valence Life Sciences. Proceeds will go toward the late-stage trial of CPX-351 liposome injection, the company's lead drug candidate for secondary acute myeloid leukemia.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC